Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cilastatin Sodium

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cilastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Cilastatin Sodium reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cilastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cilastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

    NCT02474706 · start 2016-03

    Registered record
    Registry ID
    NCT02474706
    Conditions
    Urinary Tract Infections
    Interventions
    Cefoxitin; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2017-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefoxitin; imipenem
    PhasePhase 4
    Registry statusTerminated

  • Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)

    NCT02452047 · start 2015-08-21

    Registered record
    Registry ID
    NCT02452047
    Conditions
    Bacterial Infections
    Interventions
    Imipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-21
    Completion
    2017-09-18
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionImipenem+Cilastatin/Relebactam; Colistimethate sodium (CMS); Imipenem+Cilastatin; Placebo to CMS
    PhasePhase 3
    Registry statusCompleted

  • A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

    NCT02321800 · start 2015-02-05

    Registered record
    Registry ID
    NCT02321800
    Conditions
    Urinary Tract Infections
    Interventions
    Cefiderocol; Imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02-05
    Completion
    2016-08-16
    Enrolment
    452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefiderocol; Imipenem/cilastatin
    PhasePhase 2
    Registry statusCompleted

  • Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin

    NCT02616354 · start 2015-01

    Registered record
    Registry ID
    NCT02616354
    Conditions
    Sepsis
    Interventions
    Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2015-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionImipenem
    PhasePhase 4
    Registry statusUnknown

  • Imipenem Prophylaxis in Patients With Acute Pancreatitis

    NCT02897206 · start 2014-10

    Registered record
    Registry ID
    NCT02897206
    Conditions
    Acute Pancreatitis
    Interventions
    Imipenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-12
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Pancreatitis
    InterventionImipenem; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock

    NCT02191475 · start 2014-05

    Registered record
    Registry ID
    NCT02191475
    Conditions
    Abdominal Infection
    Interventions
    glycopeptide plus carbapenem; Haizheng Li Xing ® plus tazocin ®
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2014-05
    Completion
    2017-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Infection
    Interventionglycopeptide plus carbapenem; Haizheng Li Xing ® plus tazocin ®
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis

    NCT01820026 · start 2012-12

    Registered record
    Registry ID
    NCT01820026
    Conditions
    Cirrhosis
    Interventions
    Imipenem; Vancomycin; azithromycin; Cefotaxime; Amoxicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2015-06
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    InterventionImipenem; Vancomycin; azithromycin; Cefotaxime +1 more
    PhasePhase 4
    Registry statusUnknown

  • Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

    NCT01714570 · start 2012-11

    Registered record
    Registry ID
    NCT01714570
    Conditions
    Febrile; Neutropenia; Hematopoietic Stem Cell Transplantation
    Interventions
    Piperacillin-tazobactam combination product; Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-04
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile; Neutropenia; Hematopoietic Stem Cell Transplantation
    InterventionPiperacillin-tazobactam combination product; Imipenem
    PhaseNot applicable
    Registry statusCompleted

  • A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection

    NCT01721408 · start 2012-11

    Registered record
    Registry ID
    NCT01721408
    Conditions
    Intra-abdominal Infection
    Interventions
    Tigecycline; Imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2015-10
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntra-abdominal Infection
    InterventionTigecycline; Imipenem/cilastatin
    PhasePhase 4
    Registry statusCompleted

  • Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)

    NCT01506271 · start 2012-06-01

    Registered record
    Registry ID
    NCT01506271
    Conditions
    Intra-abdominal Infections
    Interventions
    Relebactam 250 mg; Relebactam 125 mg; Imipenem/cilastatin; Matching placebo to relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06-01
    Completion
    2014-08-12
    Enrolment
    351

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntra-abdominal Infections
    InterventionRelebactam 250 mg; Relebactam 125 mg; Imipenem/cilastatin; Matching placebo to relebactam
    PhasePhase 2
    Registry statusCompleted

  • Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia

    NCT01379157 · start 2011-11

    Registered record
    Registry ID
    NCT01379157
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Imipenem; Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-07
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionImipenem; Imipenem
    PhasePhase 4
    Registry statusCompleted

  • GSK2251052 in Complicated Urinary Tract Infection

    NCT01381549 · start 2011-06-28

    Registered record
    Registry ID
    NCT01381549
    Conditions
    Infections, Urinary Tract
    Interventions
    GSK2251052; imipenem-cilastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-06-28
    Completion
    2012-03-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Urinary Tract
    InterventionGSK2251052; imipenem-cilastatin; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia

    NCT01356472 · start 2011-06

    Registered record
    Registry ID
    NCT01356472
    Conditions
    Methicillin-resistant Staphylococcus Aureus; Pneumonia, Ventilator-Associated
    Interventions
    Imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-06
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMethicillin-resistant Staphylococcus Aureus; Pneumonia, Ventilator-Associated
    InterventionImipenem/cilastatin
    PhasePhase 4
    Registry statusUnknown

  • Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections

    NCT01297842 · start 2011-05

    Registered record
    Registry ID
    NCT01297842
    Conditions
    Drug Safety
    Interventions
    Ertapenem; Meropenem or Imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Safety
    InterventionErtapenem; Meropenem or Imipenem
    PhasePhase 4
    Registry statusUnknown